Paradigm Biopharmaceuticals Limited (PBIGF)
USD 0.14
(0.0%)
USD 0.14
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -17.58 Million AUD | 68.6% |
| 2023 | -55.99 Million AUD | -43.36% |
| 2022 | -39.05 Million AUD | 44.43% |
| 2021 | -70.28 Million AUD | 31.8% |
| 2020 | -103.04 Million AUD | -42.53% |
| 2019 | -72.29 Million AUD | -2901.18% |
| 2018 | -2.4 Million AUD | 5.68% |
| 2017 | -2.55 Million AUD | 13.76% |
| 2016 | -2.96 Million AUD | 59.59% |
| 2015 | -7.32 Million AUD | -3998.45% |
| 2014 | 188.01 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -17.82 Million AUD | 46.42% |
| 2024 Q4 | -17.58 Million AUD | 1.34% |
| 2024 Q1 | -33.37 Million AUD | 40.39% |
| 2024 Q2 | -33.26 Million AUD | 0.34% |
| 2024 FY | -17.58 Million AUD | 68.6% |
| 2023 Q3 | -56.09 Million AUD | 32.85% |
| 2023 Q4 | -55.99 Million AUD | 0.19% |
| 2023 Q1 | -83.63 Million AUD | -114.14% |
| 2023 Q2 | -83.53 Million AUD | 0.12% |
| 2023 FY | -55.99 Million AUD | -43.36% |
| 2022 Q1 | -54.53 Million AUD | 22.41% |
| 2022 FY | -39.05 Million AUD | 44.43% |
| 2022 Q4 | -39.05 Million AUD | 0.38% |
| 2022 Q3 | -39.2 Million AUD | 27.67% |
| 2022 Q2 | -54.2 Million AUD | 0.6% |
| 2021 FY | -70.28 Million AUD | 31.8% |
| 2021 Q1 | -84.48 Million AUD | 18.01% |
| 2021 Q2 | -84.39 Million AUD | 0.11% |
| 2021 Q3 | -70.41 Million AUD | 16.56% |
| 2021 Q4 | -70.28 Million AUD | 0.19% |
| 2020 Q4 | -103.04 Million AUD | 0.09% |
| 2020 FY | -103.04 Million AUD | -42.53% |
| 2020 Q1 | -70.11 Million AUD | 3.01% |
| 2020 Q2 | -70 Million AUD | 0.17% |
| 2020 Q3 | -103.13 Million AUD | -47.33% |
| 2019 Q2 | -9.93 Million AUD | 0.0% |
| 2019 Q3 | -78.79 Million AUD | -693.27% |
| 2019 Q4 | -72.29 Million AUD | 8.25% |
| 2019 FY | -72.29 Million AUD | -2901.18% |
| 2019 Q1 | -9.93 Million AUD | -312.34% |
| 2018 Q1 | -6 Million AUD | -134.99% |
| 2018 Q2 | -6 Million AUD | 0.0% |
| 2018 Q3 | -2.4 Million AUD | 59.86% |
| 2018 FY | -2.4 Million AUD | 5.68% |
| 2018 Q4 | -2.4 Million AUD | 0.0% |
| 2017 Q1 | -5.02 Million AUD | -69.66% |
| 2017 FY | -2.55 Million AUD | 13.76% |
| 2017 Q4 | -2.55 Million AUD | 0.0% |
| 2017 Q3 | -2.55 Million AUD | 49.17% |
| 2017 Q2 | -5.02 Million AUD | 0.0% |
| 2016 Q1 | -5.22 Million AUD | -11244.49% |
| 2016 Q3 | -2.96 Million AUD | 43.37% |
| 2016 Q4 | -2.96 Million AUD | 0.0% |
| 2016 Q2 | -5.22 Million AUD | 0.0% |
| 2016 FY | -2.96 Million AUD | 59.59% |
| 2015 FY | -7.32 Million AUD | -3998.45% |
| 2015 Q1 | 7772.00 AUD | 0.0% |
| 2015 Q4 | 46.92 Thousand AUD | 0.0% |
| 2014 FY | 188.01 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 211.536% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 526.94% |
| SQZ Biotechnologies Company | -36.23 Million USD | 51.483% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 141.085% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -178.871% |
| Mesoblast Limited | 55.85 Million USD | 131.475% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1996.221% |
| Genus plc | 190.6 Million USD | 109.224% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 886.351% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 1548.362% |
| Marizyme, Inc. | 18.56 Million USD | 194.682% |
| ContraFect Corporation | -6.02 Million USD | -191.761% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 2685.514% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 13158.25% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 1621.642% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 884.107% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 419.553% |
| MultiCell Technologies, Inc. | 90.04 USD | 19526418.303% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -2295.371% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 235.806% |
| EV Biologics, Inc. | 1.36 Million USD | 1385.224% |
| Q BioMed Inc. | 4.06 Million USD | 533.041% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 157.542% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 2924.954% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 1844.688% |
| Biomind Labs Inc. | 711.4 Thousand USD | 2571.387% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 116.012% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 237.285% |
| Skye Bioscience, Inc. | -5.72 Million USD | -207.294% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 2143.787% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 12675.818% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 411.267% |
| IMV Inc. | 7.67 Million USD | 329.209% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 88595.983% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 898.44% |
| GB Sciences, Inc. | 1.74 Million USD | 1106.2% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -9466.183% |
| HST Global, Inc. | 96.79 Thousand USD | 18264.017% |
| CSL Limited | 10.52 Billion USD | 100.167% |
| Halberd Corporation | 144.72 Thousand USD | 12248.546% |
| Enzolytics Inc. | 981.65 Thousand USD | 1891.004% |
| Resverlogix Corp. | 6.45 Million USD | 372.539% |
| Affymax, Inc. | -5.59 Million USD | -214.124% |
| SYBLEU INC | 473.71 Thousand USD | 3811.416% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -2512.061% |
| argenx SE | -2.02 Billion USD | 99.133% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 140.479% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 62.602% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 749.095% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -98.888% |
| AVAX Technologies, Inc. | -5.9 Million USD | -197.83% |
| Zenith Capital Corp. | 10.06 Thousand USD | 174796.91% |
| Genscript Biotech Corporation | -1.06 Billion USD | 98.343% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 8871.801% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 836.85% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 10787.255% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 129.038% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 979.342% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -584.096% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 4987.686% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 186.711% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -95879.348% |
| BioStem Technologies, Inc. | 4.47 Million USD | 493.145% |
| ONE Bio Corp. | 9.04 Million USD | 294.485% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 8835.974% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -1341999.008% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 8625.726% |
| Agentix Corp. | 37.63 Thousand USD | 46820.781% |
| LadRx Corporation | -2.03 Million USD | -763.332% |
| Cell Source, Inc. | 9.23 Million USD | 290.441% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -86050.025% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2868.012% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2868.012% |
| NovAccess Global Inc. | 2.17 Million USD | 907.059% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 348.643% |
| Itoco Inc. | 228.3 Thousand USD | 7800.881% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 13028.617% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 454.68% |
| Kadimastem Ltd | -253.1 Thousand USD | -6846.408% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 4475.15% |
| CytoDyn Inc. | 20.26 Million USD | 186.771% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -2717287.481% |
| Mobile Lads Corp. | 484.23 Thousand USD | 3730.8% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -189594.131% |
| Qrons Inc. | 351.42 Thousand USD | 5102.887% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 328.153% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -6943.305% |
| Rebus Holdings, Inc. | 305 Thousand USD | 5864.425% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 494.467% |
| International Stem Cell Corporation | 2.59 Million USD | 778.822% |
| Bioxytran, Inc. | 1.89 Million USD | 1025.871% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 28269.607% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 906.158% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 611.983% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 305.559% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 2375.607% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -1306.52% |
| Neutra Corp. | 52.18 Thousand USD | 33789.419% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -606.368% |
| PureTech Health plc | -167.19 Million USD | 89.485% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -7078.817% |
| IXICO plc | -4.44 Million USD | -295.571% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 233.002% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 132.053% |
| CSL Limited | 10.52 Billion USD | 100.167% |
| Cellectis S.A. | -43.81 Million USD | 59.877% |